ClinicalTrials.gg
TerminatedNCT00573131Updated Jun 22, 2022Results posted

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

A Phase 2 interventional study of OncoGel (Paclitaxel gel) and cisplatin in Esophageal Cancer, Adenocarcinoma of the Esophagus and Squamous Cell Carcinoma, sponsored by Boston Scientific Corporation. Terminated at 20 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-22.

Sponsored by Boston Scientific Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
OncoGel did not show any impact on overall tumor response

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing paclitaxel in Esophageal Neoplasms — 11 open to participants now, 18 under way, none of them phase 3. Paclitaxel · Esophageal Neoplasms.

Enrollment
16th of 74
137 · median 40
Started
2008
with 5 others
Phase 2
48 of 80
6 open now
Registered
31st of 80
by date

Among the 80 studies testing paclitaxel in Esophageal Neoplasms, this one is the 16th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 48 in phase 2, and was the 31st registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

11 of the 80 studies testing paclitaxel in Esophageal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing paclitaxel in Esophageal Neoplasms, or all of them as a file.
02

Study summary

OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel.

The protocol is directed towards evaluating the efficacy and safety of paclitaxel delivered as a local, intralesional treatment when used in combination with chemotherapy (cisplatin and 5-FU) and radiation therapy before surgery.

Read the detailed description

The primary objective of this study is to evaluate the efficacy of OncoGel given in combination with standard chemotherapy (cisplatin and 5-FU) and radiation therapy in patients with previously untreated, resectable, local or local-regional adenosarcoma or squamous cell carcinoma.

All patients will receive IV cisplatin on Day 1 and Day 29 and IV 5-FU given continuously for 96 hours starting on Day 1 and Day 29. All patients will also receive out-patient radiation therapy for 28 treatments once per day for 5 1/2 weeks starting on Day 1.

Patients randomized to the OncoGel treatment group will have the OncoGel dose injected into their esophageal tumors during an endoscopic procedure just before starting systemic chemotherapy and radiation therapy.

All patients will have CT scans for tumor measurements before starting chemotherapy and 12 weeks later after completion of the radiation therapy and both cycles of chemotherapy.

During the chemotherapy and radiation therapy, physical exams, vital signs, routine blood tests will be performed. Patients will also be asked about their quality of life and ability to swallow.

In-patient surgery will be scheduled 4 to 6 weeks after completion of chemotherapy and radiation therapy. The resected esophagus and lymph nodes will be evaluated for the presence of residual tumor.

Patients will be followed at months 4, 5, 6, and then every 3 Months thereafter for survival and esophageal cancer status and treatment until the last patient enrolled has completed their Month 12 visit.

03

Conditions studied

  • Esophageal Cancer
  • Adenocarcinoma of the Esophagus
  • Squamous Cell Carcinoma

Keywords

  • Esophageal cancer
  • Localized esophageal cancer
  • Operable esophageal cancer
  • Loco-regional esophageal cancer
  • Esophagectomy
  • Phase 2
  • Paclitaxel
  • Tumor
  • Local
  • Chemotherapy
  • radiation therapy
  • surgery
  • OncoGel
  • Squamous cell carcinoma of the esophagus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus. Stage T2-T3, N any, M0 (no evidence of disseminated cancer except regional involvement which may be designated as "M1a"). No evidence of disease
  2. Medically able to tolerate major abdominal and/or thoracic surgery
  3. Able to undergo EUS procedure and pass EUS probe through esophageal lumen
  4. Able to receive concurrent systemic chemotherapy (cisplatin and 5-FU) and RT
  5. Clinical management plan includes esophagectomy after completion of two courses of chemoradiation therapy
  6. Performance Status of ≥ 60
  7. Minimum of 4 months
  8. Hematologic function

    • (ANC) ≥ 1500/mm3
    • count ≥ 100,000/mm3
    • ≥ 9 g/dL
  9. Hepatic function:

    • Total \< 1.5 X (ULN)
    • and ALT \< 3 X ULN
    • Albumin ≥ 3.0 g/dL or ≥ 2.0 g/dL if the lower level is considered by the investigator to be due to nutritional depletion
  10. Serum creatinine \< 1.5 mg/dL and/or ≥ 65 mL/min
  11. ≥ 18 years old
  12. If female, must be non-pregnant, nonlactating, of non-, or using adequate
  13. Capable of understanding and agreeing to fulfill the requirements of the protocol
  14. Sign the IRB/EC approved consent form

Exclusion criteria

Exclusion Criteria:

  1. History of anaphylaxis to planned CT contrast agent
  2. Prior esophageal stent insertion, laser, or photodynamic therapy
  3. Prior chest RT or major esophageal surgery
  4. Any prior receipt of cytotoxic chemotherapeutic agents
  5. Prior receipt of other cancer treatments (ie, Chelation therapy), vaccines, or biological response modifiers/growth factors (ie, GM-CSF, IL-2) within the past 4 weeks.
  6. Prior unless disease free for ≥ 3 years. Note: basal cell/squamous carcinoma of the skin, in situ cervical or breast carcinoma, or superficial transitional cell bladder carcinoma will be allowed. Subjects with a history of low risk prostatic carcinoma (ie, clinical stage 1 or 2a, Gleason score \< or = 6 and PSA \<10 ng/mL at diagnosis) will be allowed
  7. Significant currently active systemic diseases including uncontrolled diabetes, severe heart disease ( Class III or IV), uncontrolled hypertension, myocardial infarction within 3 months, severe bronchial obstruction, uncontrolled seizure disorder, or peripheral neuropathy greater than grade 1
  8. Allergies to any of the active or inactive components of OncoGel (ie, allergies to degradable PLGA [poly(lactide-co-glycolide) sutures])
  9. Receipt of an drug or device within 30 days prior to signing
  10. Any medical condition or other circumstance that, in the Investigator's opinion, would prevent completion of the study, interfere with analysis of the study results, or potentially adversely affect subject safety
  11. Known esophageal varices
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Group 1

    OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.

    Drug: OncoGel (Paclitaxel gel) · Drug: cisplatin · Drug: 5-FU · Radiation: radiation therapy · Procedure: esophageal resection

  • Active comparator
    Group 2

    Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.

    Drug: cisplatin · Drug: 5-FU · Radiation: radiation therapy · Procedure: esophageal resection

Interventions

  • 6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy

  • 75 mg/m2 IV (in the vein) once on Day 1 and Day 29

  • Drug5-FU

    1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29

  • Radiationradiation therapy

    50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks

  • Procedureesophageal resection

    Removal of esophagus after completion of chemotherapy and radiation therapy

06

What researchers measure

Primary outcomes

  1. Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT

    Per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and by Spiral CT assessment: Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) is a \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: Screening and Week 12

07

Results

Posted May 16, 2014
Limitations and caveats
Study prematurely terminated due to lack of efficacy in primary endpoint.

Participant flow

Patients were enrolled from 21 Jan 2008 through 05 Nov 2010 at 20 centers in 5 countries (United States, India, Poland, Czech Republic and Belgium).

Participant flow — Overall Study
MilestoneGroup 1Group 2
Started7265
Completed6257
Not completed108
Withdrew: Withdrawal by subject108

Outcome measures

PrimaryOverall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT

Per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and by Spiral CT assessment: Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) is a \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
Screening and Week 12
Reported as:
Number · percentage of patients
Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT
percentage of patientsGroup 1Group 2
Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT12.520.0

Adverse events

Collected over Adverse events were collected through the 12 week Assessment Period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1—30/72 (41.7%)67/72 (93.1%)
Group 2—20/65 (30.8%)55/65 (84.6%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventGroup 1Group 2
ThrombocytopeniaBlood and lymphatic system disorders1/724/65
DysphagiaGastrointestinal disorders3/724/65
LeukopeniaBlood and lymphatic system disorders3/721/65
OesophagitisGastrointestinal disorders3/721/65
Respiratory failureRespiratory, thoracic and mediastinal disorders3/721/65
NeutropeniaBlood and lymphatic system disorders0/722/65
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/722/65
Myocardial infarctionCardiac disorders2/721/65
VomitingGastrointestinal disorders2/720/65
Febrile neutropeniaBlood and lymphatic system disorders1/721/65
Most frequent other events
Showing 10 of 28
Most frequent other events
EventGroup 1Group 2
NauseaGastrointestinal disorders24/7211/65
LeukopeniaBlood and lymphatic system disorders17/728/65
VomitingGastrointestinal disorders13/7215/65
CoughRespiratory, thoracic and mediastinal disorders5/7213/65
ConstipationGastrointestinal disorders14/729/65
Weight decreasedInvestigations14/7212/65
PyrexiaGeneral disorders13/7212/65
ThrombocytopeniaBlood and lymphatic system disorders12/728/65
DiarrhoeaGastrointestinal disorders11/7210/65
Chest painGeneral disorders11/726/65

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1Group 2Total
<=18 years000
Between 18 and 65 years5548103
>=65 years171734
Age, Continuous
Age, Continuous(years)Group 1Group 2Total
Mean58.4 ± 7.257.6 ± 10.958.0 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Total
Female192140
Male534497
Region of Enrollment
Region of Enrollment(participants)Group 1Group 2Total
United States13922
Czech Republic141125
Poland8917
Belgium011
India373572
08

Study locations

20 sites
  • University of California San Diego
    San Diego, California 92093, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Indiana University Medical Center
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Digestive Health Specialists of Tyler, Texas
    Tyler, Texas 75701, United States
  • University Hospital Brno
    Brno, 62500, Czechia
  • Hospital Jablonec nad Nisou
    Jablonec nad Nisou, 466 60, Czechia
  • University Hospital Olomouc
    Olomouc, 775 20, Czechia
  • University Hospital Motol
    Praha, 150 06, Czechia
  • Massaryk's Hospital in Usti nad Labem
    Usti nad Labem, 401 13, Czechia
  • Kidwai Memorial Institute of Oncology
    Bangalore, Karnataka 560029, India
  • Amrita Institute of Medical Sciences
    Kochi, Kerala 682026, India
  • Bombay Hospital & Medical Research Centre
    Mumbai, Maharashtra 400020, India
  • Deenanath Mangeshkar Hospital
    Erandwane, Pune 411004, India
  • Meenakshi Mission Hospital and Research Centre
    Madurai, Tamil Nadu 625107, India
  • Samodzielny Publiczny Szpital Kliniczny
    Lublin, 20-081, Poland
  • Samodzielnego Publicznego Szpitala Klinicznego
    Szczecin, 70-111, Poland
09

References and documents

Publications

  • DeWitt JM, Murthy SK, Ardhanari R, DuVall GA, Wallner G, Litka P, Daugherty C, Fowers K. EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial. Gastrointest Endosc. 2017 Jul;86(1):140-149. doi: 10.1016/j.gie.2016.11.017. Epub 2016 Nov 24. PubMed 27890801 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2007
First posted
Dec 13, 2007
Start
Jan 2008
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
May 16, 2014
Last update
Jun 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00573131
Responsible party
Sponsor
First posted
Dec 13, 2007
Start date
Jan 2008
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
May 16, 2014
Last update
Jun 22, 2022

Study contacts

Kirk D Fowers, PhD
study director · Boston Scientific Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion